**Core tip:** The prevalence of nonalcoholic fatty liver disease (NAFLD) is growing gradually with the increase in population age and obesity, while effective and safe drugs for NAFLD are not yet available. HL tablet, a new botanic drug extracted from *Magnolia officinalis*, is effective in reducing hepatic fat content without any negative lipid profiles, body mass index changes and adverse effects.

INTRODUCTION
============

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide, and includes a spectrum of diseases from simple steatosis to nonalcoholic steatohepatitis (NASH), and liver cirrhosis\[[@B1]\]. Some patients with NAFLD have NASH and some of these may progress to liver cirrhosis and develop hepatocellular carcinoma\[[@B2]\]. Also, the prevalence of NAFLD is growing gradually with the increase in population age and obesity\[[@B3],[@B4]\]. Life-style change has been the most effective treatment for NAFLD\[[@B5]-[@B7]\], while effective and safe drugs for NAFLD are not yet available\[[@B1]\]. Therefore the demand for new drugs for NAFLD is increasing worldwide.

In NAFLD, visceral adipose tissue emits multiple signals that alter lipid and glucose metabolism, causing fat accumulation and a proinflammatory environment in the liver\[[@B1]\]. These effects lead to injury to the liver and other tissues. Oxidative stress, lipotoxicity, and endoplasmic reticulum and mitochondrial apoptotic pathways contribute to liver damage and promote liver fibrosis\[[@B1]\].

*Magnolia officinalis* (MO) is a traditional medicinal plant that has been used to treat liver diseases and other diseases\[[@B8]\]. Some constituents extracted from MO have been reported to have anti-inflammatory and antioxidant effects\[[@B9],[@B10]\], and MO can be effective against NAFLD. *In vitro* honokiol, extracted from MO, induced apoptosis of the activated hepatic stellate cells responsible for hepatic fibrosis\[[@B11]\]. Honokiol and magnolol extracted from MO significantly inhibited hepatic toxicity induced by galactosamine, generation of intracellular reactive oxygen species and glutathione depletion\[[@B9]\]. Also, MO inhibited lipid accumulation in free fatty acid (FFA)-exposed hepatocytes\[[@B12]\]. In another study, MO ameliorated body fat accumulation, insulin resistance, and adipose inflammation in high fat-fed mice\[[@B13]\].

We hypothesized that MO would improve steatosis and inflammation in patients with NAFLD. HL tablet is a new botanical drug extracted from MO. The aim of this study was thus to evaluate the efficacy and safety of HL tablet in the treatment of patients with NAFLD.

MATERIALS AND METHODS
=====================

Study design and population
---------------------------

Our study was a multi-center, randomized allocation, double-blind, placebo controlled, 3 group parallel, phase II trial between November 2013 and May 2015 in 3 hospitals in the Republic of Korea. It was conducted in patients with NAFLD diagnosed by ultrasonographic examination. The inclusion criteria were (1) age 19-75 years; (2) ultrasonographic features of nonalcoholic fatty liver; and (3) serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above the upper normal limits. Exclusion criteria were (1) serum AST/ALT \> 2; (2) type 1 diabetes; (3) other liver diseases (viral hepatitis, autoimmune hepatitis or biliary obstruction, *etc*.); (4) excessive alcohol consumption ≥ 30 g/d for men and ≥ 20 g/d for women; (5) use of steatogenic medications (amiodarone, methotrexate, systemic glucocorticoids, tetracycline or tamoxifen, *etc*.) within the past 3 mo; (6) serious underlying diseases (liver cirrhosis, malignancy, severe metabolic disease, serious kidney disease, serious cardiovascular disease or serious lung disease, *etc*.); (7) history of bariatric surgery within the past 6 mo; (8) contraindication for magnetic resonance spectroscopy (MRS), such as history of pacemaker implantation or shunt operation; and (9) pregnancy, breastfeeding or hypersensitivity to MO. This study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the ethics committee of each hospital, and was registered at ClinicalTrial.gov (NCT02491905).

After all the included patients had provided written informed consent, they were randomly assigned (1:1:1) to groups given high dose (400 mg) HL tablet, low dose (133.4 mg) HL tablet or placebo daily for 12 wk. Patients visited the clinic at baseline and after 4, 8, and 12 wk of treatment. At each visit, a physical examination was conducted, adverse drug events were recorded, and compliance with medication was assessed by pill counts. MRS was performed at baseline and after 12 wk of treatment. Body mass index (BMI) and blood tests such as serum AST, ALT, lipid profiles \[total cholesterol, triglycerides, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol and FFA\], and homeostasis model assessment-estimated insulin resistance (HOMA-IR) were performed at baseline and after 8 and 12 wk of treatment. A follow-up phone call related to safety was performed at 16 wk.

Assessment of hepatic fat content by MRS
----------------------------------------

MRS of the liver was performed to assess HFC at baseline and after 12 wk of treatment. MRS data were collected on 3.0T human scanners (Philips (Philips Medical Systems, Best, Netherlands) at Hanyang University Guri Hospital (site I) and Kangbuk Samsung Hospital (site II), and on a General Electric scanner (GE Healthcare, Waukesha, United States) at Dong-A University Hospital (site III). Patients were placed inside the magnet in a supine position. Prior to data collection, scout images were acquired along the three orthogonal axes in the end-exhalation breath-hold condition. To account for potential liver heterogeneity, two MRS voxels were defined in the liver (one from S5, 6 and the other from S7, 8 for each patient) avoiding major blood vessels. The edges of the voxels were at least 1 cm from the borders of the liver. A point-resolved spectroscopy (PRESS) sequence was used\[[@B14]\]. The sequence parameters for all three sites were: repetition time (TR) = 2000 ms, spectral bandwidth = 2500 Hz, 2048 data points, and voxel size = 2.5 cm × 2.5 cm × 2.5 cm. At sites I and II, data were collected under the end-exhalation breath-hold condition using echo times (TEs) = 36 and 100 ms, number of receiver channels (NRC) = 32, and number of signal averages (NSA) = 4. At site III, data were collected under the shallow breathing condition using TE = 30 and 100 ms, NRC = 20, and NSA = 8. The data acquired at the two different TEs were used for T2 collection. Immediately after each scan, the quality of the spectrum was examined based on the signal intensities and line shapes (including line widths) of the water (about 4.7 ppm) and fat (about 1.3 ppm) signals. In cases where a spectrum was considered contaminated (*e.g*., due to patient movement), the scan was repeated with the consent of the patient. After the MRS scan, the raw data were stored. The voxels in the post-treatment MRS scan were carefully co-registered with those in the pre-treatment, baseline scan by referring to the previous data (voxel locations superimposed on the scout images in the three orthogonal directions).

The MRS data were processed with a jMRUI (v5.0)\[[@B15]\]. First, they were Fourier-transformed, line-broadened and phase-corrected, and the peak areas of the water (about 4.7 ppm) and lipid (methylene at about 1.3 ppm) resonances were obtained using AMARES for the individual spectra acquired at two different TEs\[[@B16]\]. Then, the T2's of water and lipid were corrected by assuming single exponential decay. From the T2-corrected water and lipid signal intensities, a hepatic fat fraction (HFF) was calculated as lipid/(water + lipid) × 100 for each voxel. Finally, the mean HFF value over the two voxels was used as the HFC value for each patient.

Endpoints and safety evaluation
-------------------------------

The primary endpoint was the post-treatment change in HFC measured by MRS. Secondary endpoints included post-treatment changes of serum AST, ALT, cholesterol, triglycerides, FFA, HOMA-IR, and BMI. Safety assessments included adverse events, laboratory findings, vital signs and electrocardiograms. Adverse events were classified as mild, moderate or severe, and as certainly, probably/likely, possibly, not likely, and not due treatment, or not known.

Statistical analysis
--------------------

The 18 subjects in each group provided a power of 90% for identifying a difference of 4.6% in liver fat decrease between placebo and the low dose HL group. In previous studies, pioglitazone was shown to produce a 10% reduction in liver fat compared to baseline and 0% in the placebo\[[@B17]\]. Also, the 8% weight loss group in a weight loss program was shown to have a 4.6% reduction in liver fat compared to baseline\[[@B18]\]. Therefore, we considered that the high dose HL group would have a 10% reduction in liver fat compared to baseline and the low dose HL group a 4.6% reduction. To detect these levels of change, a sample size of 23 subjects in each group was needed, assuming a 20% drop-out rate.

Analyses were conducted principally by full analysis set and were supplemented by per protocol set. Continuous variables are given as mean values with SD or median values with inter-quartile ranges. Categorical variables are given as frequencies or percentages. Baseline characteristics of the placebo group and each HL group (high dose *vs* placebo, low dose *vs* placebo) were evaluated using a two sample *t*-test or Wilcoxon's rank sum test for continuous variables and Pearson's *χ*^2^ test or Fisher's exact test for categorical variables. Differences between variables were evaluated using two-sample *t*-tests or Wilcoxon's rank sum tests. Changes of HFC from baseline after 12 wk of treatment within each group were evaluated using paired *t* tests or Wilcoxon signed rank tests. *P* values \< 0.05 in 2-sided tests were considered statistically significant. SPSS 19.0 for Windows (SPSS Inc, Chicago, IL, United States) was used for all statistical analyses.

RESULTS
=======

Population
----------

A total of 104 patients were screened in this study. Of these, 74 patients with NAFLD diagnosed by ultrasonographic examination were randomly assigned to groups receiving high dose HL (*n* = 24), low dose HL (*n* = 26), and placebo (*n* = 24), respectively. Finally, a safety analysis set, full analysis set and per protocol set were analyzed in 73, 68, and 60 patients, respectively (Figure [1](#F1){ref-type="fig"}). Most of the enrolled patients completed the study (60/74; 81.1%).

![Flow chart of the study participants.](WJG-23-5977-g001){#F1}

Baseline characteristics were mostly similar in the 3 groups, as shown in Table [1](#T1){ref-type="table"}. Patients in this study had a mean age of 39.1 ± 9.5 years in the high dose HL group, 45.5 ± 11.5 years in the low dose HL group and 42.7 ± 11.2 years in the placebo group. The low dose HL group was significantly low in males compared to the placebo group (*P* = 0.044). Hepatic fat by MRS showed a tendency to be higher in the high dose HL group than the placebo group (high dose *vs* placebo: 16.1% ± 7.1% *vs* 12.0% ± 7.5%, *P* = 0.065).

###### 

Baseline characteristics of the study population

  **Characteristic**                        **High dose (*n* = 22)**   **Low dose (*n* = 23)**   **Placebo (*n* = 23)**   ***P* value**                           
  ----------------------------------------- -------------------------- ------------------------- ------------------------ --------------------------------------- ---------------------------------------
  Age, yr                                   39.1 ± 9.5                 45.5 ± 11.5               42.7 ± 11.2              0.474                                   0.355
  Males, *n* (%)                            20 (90.9)                  14 (60.9)                 20 (87.0)                1.000[1](#T1FN1){ref-type="table-fn"}   0.044[1](#T1FN1){ref-type="table-fn"}
  Height, cm                                170.1 ± 7.1                166.7 ± 10.3              170.4 ± 8.4              0.916                                   0.184
  Weight, kg                                82.4 ± 12.1                78.4 ± 16.0               82.9 ± 13.1              0.891                                   0.301
  BMI, kg/m^2^                              28.2 ± 3.4                 28.2 ± 4.0                28.4 ± 3.7               0.805                                   0.855
  Above moderate steatosis in US, *n* (%)   18 (81.8)                  16 (69.6)                 16 (69.6)                0.491[1](#T1FN1){ref-type="table-fn"}   1.000
  MRS liver fat, %                          16.1 ± 7.1                 13.3 ± 7.1                12.0 ± 7.5               0.065                                   0.526
  AST, IU/L                                 52.0 ± 19.1                58.4 ± 24.9               46.3 ± 20.5              0.461                                   0.077
  ALT, IU/L                                 89.8 ± 34.8                90.3 ± 50.9               67.4 ± 32.7              0.109                                   0.078
  Total cholesterol, mg/dL                  205.0 ± 40.3               208.1 ± 31.2              194.5 ± 36.2             0.155                                   0.179
  Triglyceride, mg/dL                       190.3 ± 80.6               210.8 ± 137.9             286.7 ± 216.1            0.308                                   0.162
  HDL cholesterol, mg/dL                    46.3 ± 7.1                 49.3 ± 10.9               43.6 ± 9.9               0.337                                   0.071
  LDL cholesterol, mg/dL                    136.0 ± 36.3               133.6 ± 29.7              118.6 ± 30.7             0.053                                   0.099
  VLDL cholesterol, mg/dL                   22.7 ± 11.2                25.3 ± 16.3               32.4 ± 21.5              0.263                                   0.214
  Free fatty acid, μEq/L                    526.2 ± 209.5              523.7 ± 341.6             581.9 ± 634.7            0.135                                   0.700
  HOMA-IR                                   2.6 ± 1.6                  2.5 ± 1.0                 3.5 ± 2.4                0.167                                   0.326[2](#T1FN2){ref-type="table-fn"}

Fisher's exact test;

Wilcoxon's rank sum test. Continuous data are expressed as mean ± SD. Categorical data are expressed as *n* (%). BMI: Body mass index; US: Ultrasonography; MRS: Magnetic resonance spectroscopy; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; HDL: High density lipoprotein cholesterol; LDL: Low density lipoprotein cholesterol; VLDL: Very low density lipoprotein cholesterol; HOMA-IR: Homeostasis model assessment-estimated insulin resistance.

Primary end point
-----------------

The mean HFC of the high dose HL group, but not of the low dose group, declined significantly after 12 wk of treatment (high dose *vs* placebo, *P* = 0.033; low dose *vs* placebo, *P* = 0.386) (Table [2](#T2){ref-type="table"}). The mean changes of HFC from baseline at week 12 were -1.7% ± 3.1% in the high dose group (*P* = 0.018), -1.21% ± 4.97% in the low dose group (*P* = 0.254) and 0.61% ± 3.87% in the placebo group (relative changes compared to baseline, high dose were: -12.1% ± 23.5%, low dose: -3.2% ± 32.0%, and placebo: 7.6% ± 44.0%) (Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). The per protocol analysis yielded similar results for the primary end points in the HL groups.

###### 

Change of hepatic fat content from baseline after 12 wk of treatment

  **Treatment group**   **Full analysis set**   **Per protocol set**                                                                                             
  --------------------- ----------------------- ---------------------- -------------- --------------------------------------- ---- -------------- -------------- ---------------------------------------
  Placebo, %            23                      11.96 ± 7.46           12.57 ± 8.34                                           20   12.59 ± 7.70   13.59 ± 8.47   
  Low dose, %           23                      13.33 ± 7.11           12.12 ± 6.33   0.386[1](#T2FN1){ref-type="table-fn"}   20   12.99 ± 6.86   11.37 ± 6.02   0.164[1](#T2FN1){ref-type="table-fn"}
  High dose, %          22                      16.05 ± 7.05           14.34 ± 7.19   0.033[2](#T2FN2){ref-type="table-fn"}   20   16.12 ± 7.19   14.77 ± 7.15   0.039[2](#T2FN2){ref-type="table-fn"}

Two sample *t*-test;

Wilcoxon's rank sum test. Continuous data are expressed as mean ± SD.

![Changes of hepatic fat content from baseline after 12 wk of treatment.](WJG-23-5977-g002){#F2}

Secondary end points
--------------------

Secondary end points are shown in Table [3](#T3){ref-type="table"}. There was a modest but non-significant decrease in serum ALT level in both HL groups (*vs* high dose: -12.73 ± 29.30 IU/L, *P* = 0.097; *vs* low dose: -13.65 ± 39.56 IU/L, *P* = 0.153). Serum AST levels were similar in all three groups.

###### 

Secondary endpoint changes from baseline after 12 wk of treatment (full analysis set)

  **Variable**               **High dose (*n* = 22)**   **Low dose (*n* = 23)**   **Placebo (*n* = 23)**   ***P* value**   
  -------------------------- -------------------------- ------------------------- ------------------------ --------------- -------
  AST, IU/L                  -7.82 ± 20.59              -2.74 ± 33.79             -2.96 ± 21.19            0.865           0.397
  ALT, IU/L                  -12.73 ± 29.30             -13.65 ± 39.56            -0.17 ± 19.58            0.097           0.153
  Total cholesterol, mg/dL   -7.86 ± 27.92              2.22 ± 32.89              -0.61 ± 22.47            0.532           0.613
  Triglyceride, mg/dL        -16.50 ± 52.47             29.57 ± 186.19            -86.91 ± 157.20          0.041           0.031
  HDL cholesterol, mg/dL     1.32 ± 14.98               -1.78 ± 8.71              1.83 ± 8.62              0.289           0.567
  LDL cholesterol, mg/dL     9.05 ± 27.78               -5.35 ± 23.63             5.74 ± 19.98             0.088           0.253
  VLDL cholesterol, mg/dL    0.43 ± 12.05               9.52 ± 27.85              -9.77 ± 17.47            0.047           0.007
  Free fatty acid, μEq/L     -73.23 ± 283.52            15.70 ± 304.68            -73.87 ± 666.93          0.146           0.921
  HOMA IR                    -0.01 ± 1.41               0.18 ± 0.77               -1.32 ± 2.44             0.174           0.019
  BMI, kg/m^2^               0.01 ± 0.81                -0.06 ± 0.97              -0.20 ± 0.80             0.608           0.904

Continuous data are expressed as mean ± SD. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; HDL: High density lipoprotein cholesterol; LDL: Low density lipoprotein cholesterol; VLDL: Very low density lipoprotein cholesterol; HOMA-IR: Homeostasis model assessment-estimated insulin resistance.

Levels of triglycerides decreased significantly in the placebo group (-86.91 ± 157.20 mg/dL) compared with each HL group (*vs* high dose: -16.50 ± 52.47 mg/dL, *P* = 0.041; *vs* low dose: 29.57 ± 186.19 mg/dL, *P* = 0.031). And levels of VLDL cholesterol also decreased significantly in the placebo group (-9.77 ± 17.47 mg/dL) compared with the HL groups (*vs* high dose: 0.43 ± 12.05 mg/dL, *P* = 0.047; *vs* low dose: 9.52 ± 27.85 mg/dL, *P* = 0.007). Other lipid profiles (total cholesterol, HDL cholesterol, LDL cholesterol, and FFA) were similar in the three groups, as was BMI. A small decrease in HOMA-IR, was observed in the placebo group whereas no change was seen in the low HL group (*P* = 0.019). However, there was no difference in HOMA-IR between placebo and the high HL group. Per protocol analysis yielded a similar pattern for secondary end points (Supplement Table 1).

Safety
------

Four patients (17.4%) treated with high dose HL, 10 patients (38.5%) treated with low dose HL and 9 placebo patients (37.5%) experienced at least one adverse event (Supplementary Table 2). Treatment-related adverse events are shown in Table [4](#T4){ref-type="table"}. All the treatment-related adverse events were mild, and no patient was withdrawn because of a treatment-related events.

###### 

Treatment-related adverse events during the study *n* (%)

  **System organ class preferred term**   **High dose (*n* = 23)**   **Low dose (*n* = 26)**   **Placebo (*n* = 24)**
  --------------------------------------- -------------------------- ------------------------- ------------------------
  Gastrointestinal disorders                                                                   
  Abdominal pain upper                    0                          1 (3.85)                  0 (0)
  Nausea                                  0                          0 (0)                     1 (4.17)
  Nervous system disorders                                                                     
  Dizziness                               0                          1 (3.85)                  0 (0)

DISCUSSION
==========

In this randomized, double-blind and placebo-controlled study, we evaluated the efficacy and safety of HL tablet extracted from MO for hepatic fat reduction in patients with NAFLD. Treatment with HL tablet for 12 wk lowered hepatic fat measured by MRS and did not result in any negative lipid profiles or changes of BMI. The HL tablet was well-tolerated.

At the present time, no effective and safe pharmacologic therapy for patients of NAFLD is available\[[@B1]\]. Weight loss due to life style modifications such as diet and excise has been the most effective therapy for NAFLD, leading to reduction of intrahepatic fat content; however, maintaining such benefits is difficult\[[@B1],[@B19]\]. Pioglitazone, a PPAR-γ agonist, significantly decreased HFC, FFA levels and insulin resistance in patients with NASH, and improved histologic findings such as hepatic steatosis and inflammation\[[@B17],[@B20],[@B21]\]. However long-term administration of pioglitazone carries risks of weight gain, postmenopausal bone loss or malignancies such as bladder cancer\[[@B20]-[@B24]\]. Vitamin E is an antioxidant, and high dose RRR-α-tocopherol (800 IU/d) improves serum AST levels, serum ALT levels and histologic findings\[[@B20]\], but safety concerns have also been raised about long-term administration of vitamin E\[[@B1]\]. Obeticholic acid (OCA, 6α-ethyl-chenodeoxycholic acid), a farnesoid X receptor agonist, is receiving attention for patients with NAFLD\[[@B25]\]. In phase IIb randomized trial (the FLINT study), OCA led to histological improvement, including reduced hepatic fibrosis in non-cirrhotic patients with NASH\[[@B26]\]. However, histological improvement was seen in only 45% of those treated with OCA, and pruritus, the main side effect, occurred in 23% of the patients\[[@B26]\].

The reason for progression from simple steatosis to NASH is not clear. However, the most likely idea is that triglycerides accumulate in hepatocytes due to increased peripheral insulin resistance ("first hit" theory), and then oxidative stress causes fat peroxidation, liver cell damage and inflammatory cytokine activation (\"second hit\" theory)\[[@B27]\]. This implies that fat accumulation in hepatocytes is the initial cause of NASH. Given that fat accumulation in hepatocytes can lead to NASH, reducing intrahepatic fat by treatment with HL tablet would be a key to preventing the \"first hit\" leading to NAFLD and this would prevent the transition to NASH. Furthermore, despite treatment for only 12 wk, there was a significant reduction of mean HFC in the high HL group, and we anticipate that treatment for 24 wk would have a greater effect.

In patients with NAFLD, elevation in serum ALT may correlate with HFC and insulin resistance\[[@B28]\]. HOMA-IR has been extensively used as a marker of insulin resistance in large population epidemiology studies. In the present study there was no improvement of HOMA-IR in the high HL group but serum ALT levels showed a modest though non-significant decrease in the HL groups. Though we did not carry out any liver biopsies in this study and HOMA-IR is not the gold standard for measuring insulin resistance\[[@B29]\], our results suggest that HL tablet may improve not only insulin resistance but also NASH. Longer-term studies of insulin resistance with use of higher doses of HL tablet are needed.

We observed no significant difference in most lipid profiles between the placebo group and the HL groups. However, surprisingly, levels of triglyceride and of VLDL cholesterol were significantly lower in the placebo group than either HL group. Because this study was a randomized, double-blind and placebo-controlled study and routine treatment was simultaneously performed, we recommended life style modifications to the patients as NAFLD treatment. Also, the enrolled patients knew that they suffered from NAFLD, and had the good sense to undertake life style modifications. Although this is not certain, we presume that these unexpected results occurred because the placebo group complied better with the suggested life style modifications than either HL tablet group.

HL tablet was well-tolerated by the patients. All treatment-related adverse events were mild. Because HL tablet does not cause weight gain, unlike pioglitazone, this will lead to few harmful effects in patients with metabolic syndrome such as diabetes and dyslipidemia\[[@B30]\].

This study had several limitations. First, it involved a relatively small number of patients and a short duration of treatment, because it was a phase II clinical trial. Second, since liver biopsies were not performed, we do not know how many patients with NASH were included in the study and cannot discuss any histologic findings. However, since patients with NAFLD in this study were excluded those with serum AST/ALT ratio \> 2 and had higher baseline serum ALT level than serum AST level (AST/ALT ratio \< 1), we think that more patients with simple steatosis than with advanced liver fibrosis were included\[[@B31]\].

In conclusion, HL tablet is effective in reducing HFC in short-term treatment (12 wk) without causing any negative lipid profiles, BMI changes and serious adverse effects. It may be a new and effective drug for treating NAFLD. Larger trials are warranted to assess the long-term efficacy of HL tablet in patients with NAFLD.
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